Mediwound (MDWD) has released an update.
MediWound Ltd. announced a positive outlook with a $5 million revenue in Q1 2024, driven by the burgeoning interest in its product NexoBrid®, and a forecast of $24 million for the year. The company is on track for its mid-2024 manufacturing facility completion and plans to initiate a Phase III study for EscharEx® in the second half of the year. MediWound is also poised to join the Russell 3000® Index, marking a significant corporate development.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
